513 related articles for article (PubMed ID: 30851964)
1. An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.
Galbusera M; Noris M; Gastoldi S; Bresin E; Mele C; Breno M; Cuccarolo P; Alberti M; Valoti E; Piras R; Donadelli R; Vivarelli M; Murer L; Pecoraro C; Ferrari E; Perna A; Benigni A; Portalupi V; Remuzzi G
Am J Kidney Dis; 2019 Jul; 74(1):56-72. PubMed ID: 30851964
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.
Noris M; Galbusera M; Gastoldi S; Macor P; Banterla F; Bresin E; Tripodo C; Bettoni S; Donadelli R; Valoti E; Tedesco F; Amore A; Coppo R; Ruggenenti P; Gotti E; Remuzzi G
Blood; 2014 Sep; 124(11):1715-26. PubMed ID: 25037630
[TBL] [Abstract][Full Text] [Related]
3. Modeling complement activation on human glomerular microvascular endothelial cells.
Stevens KH; Baas LM; van der Velden TJAM; Bouwmeester RN; van Dillen N; Dorresteijn EM; van Zuilen AD; Wetzels JFM; Michels MAHM; van de Kar NCAJ; van den Heuvel LP
Front Immunol; 2023; 14():1206409. PubMed ID: 37954621
[TBL] [Abstract][Full Text] [Related]
4. Complement Activation and Thrombotic Microangiopathies.
Palomo M; Blasco M; Molina P; Lozano M; Praga M; Torramade-Moix S; Martinez-Sanchez J; Cid J; Escolar G; Carreras E; Paules C; Crispi F; Quintana LF; Poch E; Rodas L; Goma E; Morelle J; Espinosa M; Morales E; Avila A; Cabello V; Ariceta G; Chocron S; Manrique J; Barros X; Martin N; Huerta A; Fraga-Rodriguez GM; Cao M; Martin M; Romera AM; Moreso F; Manonelles A; Gratacos E; Pereira A; Campistol JM; Diaz-Ricart M
Clin J Am Soc Nephrol; 2019 Dec; 14(12):1719-1732. PubMed ID: 31694864
[TBL] [Abstract][Full Text] [Related]
5. Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.
Xie L; Nester CM; Reed AI; Zhang Y; Smith RJ; Thomas CP
Transplant Proc; 2012 Dec; 44(10):3037-40. PubMed ID: 23195022
[TBL] [Abstract][Full Text] [Related]
6. Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.
Magro CM; Momtahen S; Mulvey JJ; Yassin AH; Kaplan RB; Laurence JC
Am J Dermatopathol; 2015 May; 37(5):349-56; quiz 357-9. PubMed ID: 25893747
[TBL] [Abstract][Full Text] [Related]
7. Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.
Vondrák K; Seeman T
Transplant Proc; 2018 Apr; 50(3):967-970. PubMed ID: 29661469
[TBL] [Abstract][Full Text] [Related]
8. Liver transplantation for aHUS: still needed in the eculizumab era?
Coppo R; Bonaudo R; Peruzzi RL; Amore A; Brunati A; Romagnoli R; Salizzoni M; Galbusera M; Gotti E; Daina E; Noris M; Remuzzi G
Pediatr Nephrol; 2016 May; 31(5):759-68. PubMed ID: 26604087
[TBL] [Abstract][Full Text] [Related]
9. A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.
Schalk G; Kirschfink M; Wehling C; Gastoldi S; Bergmann C; Hoppe B; Weber LT
Pediatr Nephrol; 2015 Jun; 30(6):1039-42. PubMed ID: 25752761
[TBL] [Abstract][Full Text] [Related]
10. Three months interval therapy of Eculizumab in a patient with atypical hemolytic uremic syndrome with hybrid CFHR1/CFH gene.
Alobaidi S; AlDabbagh A; Alamoudi A; Almowarey M; Akl A
CEN Case Rep; 2019 May; 8(2):139-143. PubMed ID: 30715674
[TBL] [Abstract][Full Text] [Related]
11. Ex Vivo Test of Complement Dysregulation in Atypical Hemolytic Uremic Syndrome Kidney Transplant patients: A Pilot Study.
Duineveld C; Bouwmeester RN; van den Heuvel LPWJ; van de Kar NCAJ; Wetzels JFM
Kidney Int Rep; 2024 Jan; 9(1):145-151. PubMed ID: 38312782
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome.
Greenbaum LA; Fila M; Ardissino G; Al-Akash SI; Evans J; Henning P; Lieberman KV; Maringhini S; Pape L; Rees L; van de Kar NC; Vande Walle J; Ogawa M; Bedrosian CL; Licht C
Kidney Int; 2016 Mar; 89(3):701-11. PubMed ID: 26880462
[TBL] [Abstract][Full Text] [Related]
13. Eculizumab Modifies Outcomes in Adults with Atypical Hemolytic Uremic Syndrome with Acute Kidney Injury.
Cao M; Leite BN; Ferreiro T; Calvo M; Fernández C; Alonso Á; Rodriguez A; Salvador P; Seijo R; Pita S; Arjona E; Rodríguez de Córdoba S; Valdés Cañedo F
Am J Nephrol; 2018; 48(3):225-233. PubMed ID: 30205388
[TBL] [Abstract][Full Text] [Related]
14. Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.
Kato H; Miyakawa Y; Hidaka Y; Inoue N; Ito S; Kagami S; Kaname S; Matsumoto M; Mizuno M; Matsuda T; Shimono A; Maruyama S; Fujimura Y; Nangaku M; Okada H
Clin Exp Nephrol; 2019 Jan; 23(1):65-75. PubMed ID: 29959568
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab Dosing Regimen in Atypical HUS: Possibilities for Individualized Treatment.
Volokhina E; Wijnsma K; van der Molen R; Roeleveld N; van der Velden T; Goertz J; Sweep F; Brüggemann RJ; Wetzels J; van de Kar N; van den Heuvel L
Clin Pharmacol Ther; 2017 Oct; 102(4):671-678. PubMed ID: 28295239
[TBL] [Abstract][Full Text] [Related]
16. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome.
Cugno M; Gualtierotti R; Possenti I; Testa S; Tel F; Griffini S; Grovetti E; Tedeschi S; Salardi S; Cresseri D; Messa P; Ardissino G
J Thromb Haemost; 2014 Sep; 12(9):1440-8. PubMed ID: 24853860
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Variable Pharmacokinetic Profile of Eculizumab in an aHUS Patient.
Bouwmeester RN; Ter Avest M; Wijnsma KL; Duineveld C; Ter Heine R; Volokhina EB; Van Den Heuvel LPWJ; Wetzels JFM; van de Kar NCAJ
Front Immunol; 2020; 11():612706. PubMed ID: 33519821
[TBL] [Abstract][Full Text] [Related]
18. An
Gastoldi S; Aiello S; Galbusera M; Breno M; Alberti M; Bresin E; Mele C; Piras R; Liguori L; Santarsiero D; Benigni A; Remuzzi G; Noris M
Front Immunol; 2023; 14():1112257. PubMed ID: 36845135
[TBL] [Abstract][Full Text] [Related]
19. Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.
Fakhouri F; Fila M; Provôt F; Delmas Y; Barbet C; Châtelet V; Rafat C; Cailliez M; Hogan J; Servais A; Karras A; Makdassi R; Louillet F; Coindre JP; Rondeau E; Loirat C; Frémeaux-Bacchi V
Clin J Am Soc Nephrol; 2017 Jan; 12(1):50-59. PubMed ID: 27799617
[TBL] [Abstract][Full Text] [Related]
20. Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.
Puissant-Lubrano B; Puissochet S; Congy-Jolivet N; Chauveau D; Decramer S; Garnier A; Huart A; Kamar N; Ribes D; Blancher A
Clin Immunol; 2017 Oct; 183():1-7. PubMed ID: 28647502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
